Clovis Oncology Inc
NASDAQ:CLVS
Clovis Oncology Inc
NASDAQ:CLVS
Price:
0.093 USD
3.33%
Market Closed
Updated:
May 18, 2024
Clovis Oncology Inc
Operating Expenses
|
Clovis Oncology Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clovis Oncology Inc
NASDAQ:CLVS
|
Operating Expenses
-$330.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$20.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Clovis Oncology Inc's Operating Expenses?
Operating Expenses
-330.2m
USD
-330.2m
USD
Based on the financial report for Dec 31, 2021, Clovis Oncology Inc's Operating Expenses amounts to -330.2m USD.
What is Clovis Oncology Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-3%
-3%
Over the last year, the Operating Expenses growth was 22%. The average annual Operating Expenses growth rates for Clovis Oncology Inc have been 7% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
